cyc116
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00560716)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
KDR inhibitor
Pan-Aurora kinase inhibitor
Serine/threonine-protein kinase Aurora inhibitor
Pan-Aurora kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1- Mol. weight
- 368.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL482967 ↗
Also known as
- 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine
- cyc116
- cyc116
- cyc116
- cyc116
- cyc 116
- cyc-116
- cyc-116
- cyc-116
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00560716 | Phase 1 | Jun 1, 2007 | Cyclacel Pharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1